Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Company Deals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Fineline Cube Apr 16, 2026
Company Drug

Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance

Fineline Cube Jul 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...

Company Deals

SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare

Fineline Cube Jul 18, 2024

Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new...

Company Deals

Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio

Fineline Cube Jul 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive...

Company Deals

China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions

Fineline Cube Jul 18, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...

Company Drug

Everest Medicines’ Nefecon Receives NMPA Review, Signaling Potential Treatment Milestone for IgAN Patients

Fineline Cube Jul 18, 2024

Everest Medicines (HKG: 1952), a biopharmaceutical company dedicated to addressing critical medical needs in Asian...

Company

Sanofi to Bolster Hyderabad Facility with $437M Investment, Eyeing Tech Upgrades

Fineline Cube Jul 18, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a leading French multinational pharmaceutical company, has announced plans to...

Company Deals

CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance

Fineline Cube Jul 18, 2024

In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and...

Company Drug

Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China

Fineline Cube Jul 18, 2024

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...

Company Deals

Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai

Fineline Cube Jul 17, 2024

China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish...

Company Deals

Eisai Co., Ltd Secures Asia-Pacific Rights for Fungal Drug with Sato Pharma Deal

Fineline Cube Jul 17, 2024

Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic...

Company Deals

Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie

Fineline Cube Jul 17, 2024

US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm...

Company Drug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo (efgartigimod alfa SC) in gMG

Fineline Cube Jul 17, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE (NASDAQ: ARGX)...

Company Drug

Mabwell Bioscience Lands Orphan Drug Status for B7-H3 Targeting ADC in Small Cell Lung Cancer

Fineline Cube Jul 17, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has been granted Orphan Drug Designation (ODD) by...

Company Drug

Shanghai Pharmaceuticals Secures NMPA Nod for Roche’s Valcyte Generic

Fineline Cube Jul 17, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that it has received marketing approval...

Company Deals

Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs

Fineline Cube Jul 17, 2024

Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research...

Company Drug

Jiangsu Simcere Pharmaceutical’s Quviviq Approval Application Accepted for Review by China’s NMPA

Fineline Cube Jul 17, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), in partnership with Swiss pharmaceutical firm Idorsia Pharmaceuticals...

Company

Jiangsu Hengrui Pharmaceuticals Faces FDA Setback with Warning Letter for Quality Control Issues

Fineline Cube Jul 17, 2024

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a...

Company Drug

Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China

Fineline Cube Jul 17, 2024

Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...

Company Drug

Sino Biopharmaceutical’s Anlotinib Achieves Milestones in Phase III Trial for Soft-Tissue Sarcoma

Fineline Cube Jul 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive...

Company Deals

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

Fineline Cube Jul 17, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Posts pagination

1 … 315 316 317 … 652

Recent updates

  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
  • Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
  • Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.